Related Experiment Video

Updated: May 23, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Severe organophosphate poisoning with delayed cholinergic crisis, intermediate syndrome and organophosphate induced

Aklilu Azazh1

  • 1Department of Emergency Medicine, Medical Faculty, Addis Ababa University.

Ethiopian Journal of Health Sciences
|March 22, 2012
PubMed

Insights

Organophosphate poisoning can cause rare complications like Intermediate Syndrome and Delayed Polyneuropathy. This case highlights these severe, successive issues in Ethiopia, urging greater healthcare awareness.

Area of Science:

  • Toxicology
  • Neurology
  • Clinical Medicine

Background:

  • Organophosphate compounds are widely used pesticides with significant neurotoxic potential.
  • Exposure can lead to a spectrum of acute and subacute clinical manifestations, including cholinergic crisis, Intermediate Syndrome, and Delayed Central Nervous System Complications.

Purpose of the Study:

  • To report the first documented case of Organophosphate Poisoning complicated by both Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy in Ethiopia.
  • To increase awareness among healthcare workers regarding these rare but severe complications of a common poisoning.

Main Methods:

  • Case report of a patient with severe Organophosphate Poisoning.
  • Detailed clinical observation and documentation of successive rare complications.

Main Results:

  • The patient presented with severe Organophosphate Poisoning.
  • The patient developed a succession of rare complications, including Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy.

Conclusions:

  • Organophosphate Poisoning can present with a complex and sequential pattern of rare neurological complications.
  • This case underscores the importance of recognizing and managing Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy in patients with severe organophosphate exposure.
  • Enhanced awareness and diagnostic capabilities are crucial for healthcare providers in regions where organophosphate exposure is prevalent.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...